At present, controlled evidence indicates that IL-6 inhibition is marginally o not effective for COVID-19, whereas several uncontrolled studies evaluating IL-1 inhibition yielded overall promising results and are awaiting validation in controlled settings. This evidence concerns the gene IL1B and COVID-19.